Samsung Biologics updates on deal with Pfizer

4 July 2023

South Korean contract development and manufacturing organization (CDMO) Samsung Biologics (KRX: 207940) today provided an update on the deal it announced last month with US pharma major Pfizer (NYSE: PFE).

Samsung Biologics and Pfizer have signed two agreements for the long-term manufacturing of Pfizer’s multiproduct biosimilar portfolio, worth $897 million in total.

Deal 1: Amended agreement of a deal initially signed in March 2023, which was announced to be increased by $193 million in a Letter of Intent (LOI) publicized on June 8.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK